Gilles Salles
Memorial Sloan Kettering Cancer Center · Hospices Civils de Lyon · Service d'Hématologie Clinique, Centre Hospitalier Lyon Sud, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gilles Salles as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:14 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03939182 · Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell LymphomaMemorial Sloan Kettering Cancer Center · completed · Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma · principal investigator
- N/ANCT03868527 · The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.Hospices Civils de Lyon · unknown · Hematologic Diseases · principal investigator
- Ph1/Ph2NCT03225924 · Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by ChemiotherapyThe Lymphoma Academic Research Organisation · terminated · DLBCL · principal investigator
- N/ANCT02520895 · Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic LeukemiaHospices Civils de Lyon · completed · LYMPHOMA · principal investigator
- Ph1NCT02055924 · Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell LymphomasThe Lymphoma Academic Research Organisation · terminated · B-cell Lymphoma · study chair
- Ph1NCT01766583 · A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell LymphomaThe Lymphoma Academic Research Organisation · completed · Relapsed/Refractory B-cell Lymphoma · study chair
- Ph1NCT01551524 · Phase I Study of mPEG-R-Crisantaspase Given IVJazz Pharmaceuticals · completed · Hematologic Malignancies · principal investigator
- N/ANCT00169598 · Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised StudyHospices Civils de Lyon · unknown · Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Development of Mechanism-Based Therapy For Myc+/Bcl2+ Diffuse Large B Cell LymphomaP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2020 · $273,372 awarded in 2020Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:14 UTC. The ranking covers the 200 most relevant of 189 PubMed records, and a shared surname and initials can bring in a namesake. All 189 on PubMed
- CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med · 20024,570 citationsRCR 94.6
- 3,432 citationsRCR 128.5
- 1,530 citationsRCR 29.2
- Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.J Clin Oncol · 20051,166 citationsRCR 25.9
- PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.N Engl J Med · 2014894 citationsRCR 24.0
- 855 citationsRCR 20.8
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.N Engl J Med · 2022835 citationsRCR 63.5
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.Lancet Oncol · 2022591 citationsRCR 38.4
- 563 citationsRCR 23.2
- 524 citationsRCR 26.6